The FDA grants Fast Track designation to sonelokimab for moderate to severe palmoplantar pustulosis, a chronic inflammatory skin disease.

“EFFISAYIL™ 2 is the first and largest multinational randomized clinical trial to evaluate a treatment for the prevention of GPP flares,” said Bruce Strober, MD, PhD, Clinical Professor, Dermatology, ...

New top-line data from a global Phase 3 clinical trial of patients with generalized pustular psoriasis (GPP) flares show rapid clearance of pustulation, erythema and scaling through four weeks after a ...

Cutaneous manifestations are common among patients with pediatric autoinflammatory bone diseases and may precede bone involvement.

PP affects men and women in a ratio of 4:1. 2 Most severe infections occur in the elderly. Risk factors include tinea pedis; diabetes mellitus; hyperhidrosis; excessive participation in water sports; ...

Imsidolimab is a humanized IgG4 antibody that inhibits the function of the interleukin-36-receptor. Treatment with imsidolimab led to significant clearance of pustulation, erythema, and scaling in ...

Please provide your email address to receive an email when new articles are posted on . The mean annualized flare rate per patient per year was 0.91, with a mean time of 5.9 months between flares.

Scalp rosacea is an uncommon skin condition causing discoloration or redness and pus-filled bumps on the top of the head. It tends to affect males in an atypical pattern. Rosacea is a chronic skin ...

Tender, rupturing pustule on the chin A man complained of mild-to-moderate sensitivity in his lower incisor whenever he chewed for the past year. Four months ago, a painful tender swelling developed ...